- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02300792
The Effects of Honey, as a Dietary Supplement in Children With Hepatitis A
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a randomized, placebo controlled double-blinded clinical trial, which was conducted at the Children's Hospital of Ain Shams university during the period from November 2013 to May 2014. Eligible patients were previously healthy children of both sexes, aged 2 to 18 years, who developed manifestations of acute hepatitis. Patients with diabetes mellitus (DM), chronic liver diseases, autoimmune disorders, renal disorders, neurologic diseases or malignancy were excluded from the study. Eighty nine eligible patients were recruited from the outpatient Clinic of the Children's Hospital of Ain Shams university and were subjected to history taking, physical examination and laboratory investigations in the form of serum alanine aminotransferase (ALT), serum aspartate aminotransferase (AST), serum gamma gultamyltransferase (GGT), serum bilirubin (total and direct) and assay for Hepatitis A Virus IgM (HAV IgM). Only patients who had positive HAV IgM were candidates for this study. They were seventy six patients who were randomly assigned following simple randomisation procedure (computerized random numbers) to 1 of 2 groups with a 1:1 allocation ratio.
During the study, a total of twenty six patients were excluded; nine patients stopped the trial because they refused to repeat blood sampling for investigations, six patients were not compliant to honey intake and ten patients lost follow up. Fifty patients, thus completed the study protocol and were included in the final analysis.
Assuming the mean duration of the acute illness is 6 weeks and the mean (±SD) duration of acute illness in the intervention group is 4 (±2), a total sample size of 42 patients (21 per group) is required to have a statistical power of 90% (alpha=0. 05). Post- hoc test was used for power calculation.
Each patient in the intervention group (group 1) took oral honey in a dose of 5 ml/kg/day (with a maximum dose of 150 ml/day) for four weeks. The dose of honey was empirical.
Each patient in the placebo group (group 2) took 5 ml molasses/kg/day; with a maximum of 150ml/day. Molasses is a honey-like substance made when cane sugar is processed. It contains no fat and is composed mainly of sucrose, besides some fructose and glucose.
The main outcome measure was the recovery time defined as the number of days from the start of the intervention to subsidence of symptoms and signs of hepatitis and return of liver transaminases to their normal levels. The main symptoms and signs of hepatitis A are fever, anorexia, nausea, vomiting, abdominal pain, dark urine, clay-colored stools and jaundice. Physical examination focused on general condition, vital data, jaundice, hepatosplenomegaly and ascites. The laboratory work up consisted of measurements of ALT, AST and GGT by kinetic method, measurement of total and direct bilirubin levels by colorimetric method, and assay of Anti-HAV IgM by ELISA.
Clinical and laboratory evaluation of each patient was done at baseline (0), 2nd week and 4th week (endpoint).
Study Type
Enrollment (Actual)
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Previously healthy children who have Hepatitis A.They were of both sexes and aged 2 to 18 years.
Exclusion Criteria:
Patients with diabetes mellitus (DM), chronic liver diseases, autoimmune disorders, renal disorders, neurologic diseases or malignancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: honey
Each patient in the honey group (group 1) took oral honey in a dose of 5 ml/kg/day (with a maximum dose of 150 ml/day) for four weeks.
|
Each patient in the intervention group (group 1) took oral honey in a dose of 5 ml/kg/day (with a maximum dose of 150 ml/day) for four weeks.
Each patient in the molasses (placebo) group took 5 ml molasses/kg/day for four weeks, with a maximum of 150 ml/day
Other Names:
|
Placebo Comparator: molasses
Each patient in the molasses (placebo) group (group 1) took molasses in a dose of 5 ml/kg/day (with a maximum dose of 150 ml/day) for four weeks.
|
Each patient in the intervention group (group 1) took oral honey in a dose of 5 ml/kg/day (with a maximum dose of 150 ml/day) for four weeks.
Each patient in the molasses (placebo) group took 5 ml molasses/kg/day for four weeks, with a maximum of 150 ml/day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
the recovery time defined as the number of days from the start of the intervention to subsidence of symptoms and signs of hepatitis and return of liver transaminases to their normal levels.
Time Frame: 4 weeks
|
4 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mamdouh A Abdulrhman, Professor, Ain Shams University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 11/013
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis A
-
Boryung Pharmaceutical Co., LtdCompletedHepatitis A VaccineKorea, Republic of
-
Merck Sharp & Dohme LLCCompletedHepatitis A Virus Infection
-
Sanofi Pasteur, a Sanofi CompanyCompletedHepatitis A | Hepatitis A VirusChina
-
Boryung Pharmaceutical Co., LtdCompletedHepatitis A VaccineKorea, Republic of
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedHepatitis | Acute Hepatitis APanama
-
Grifols Therapeutics LLCCompletedAnti-Hepatitis A Antibody Levels in Heathy SubjectsUnited States
-
Merck Sharp & Dohme LLCCompleted
-
Boryung Biopharma Co., Ltd.Not yet recruitingHepatitis A | Hep AKorea, Republic of, Thailand
-
University of Maryland, BaltimoreAlexandria University; MADAUS GmbH; The Egyptian Company for Blood Transfusion... and other collaboratorsTerminatedAcute Hepatitis C | Acute Hepatitis B | Acute Hepatitis A | Acute Hepatitis E | Acute EBV Hepatitis | Acute CMV HepatitisEgypt
Clinical Trials on honey
-
Postgraduate Medical Institute, LahoreCompleted
-
Ain Shams UniversityCompleted
-
Agricultural University of AthensCompletedAppetitive Behavior | Potential Abnormality of Glucose ToleranceGreece
-
Celal Bayar UniversityRecruiting
-
Universiti Sains MalaysiaRecruitingDiabetes Mellitus | Diabetes | Wound Heal | HoneyMalaysia
-
Providence University, TaiwanUnknown
-
Waiariki Institute of TechnologyManuka Health New ZealandCompleted
-
All India Institute of Medical Sciences, New DelhiPostgraduate Institute of Medical Education and Research; Jawaharlal Institute...CompletedPressure Ulcer | Critically Ill Children | Pressure Sore | Bed SoreIndia
-
mamdouh abdulmaksoud abdulrhmanCompletedIdiopathic Dilated Cardiomyopathy
-
Ain Shams UniversityCompletedAcute Lymphoblastic LeukemiaEgypt